The role of checkpoints in the treatment of GBM

Jennifer E. Kim, Michael Lim

Research output: Contribution to journalArticle

Abstract

Targeted immunotherapy is founded on the principle that augmentation of effector T cell activity in the tumor microenvironment can translate to tumor regression. Targeted checkpoint inhibitors in the form of agonist or antagonist monoclonal antibodies have come to the fore as a promising strategy to activate systemic immunity and enhance T cell activity by blocking negative signals, enhancing positive signals, or altering the cytokine milieu. This review will examine several immune checkpoints and checkpoint modulators that play a role in cancer pathogenesis, with an emphasis on malignant gliomas.

Original languageEnglish (US)
Pages (from-to)413-423
Number of pages11
JournalJournal of Neuro-Oncology
Volume123
Issue number3
DOIs
StatePublished - Jul 23 2015

Fingerprint

T-Lymphocytes
Tumor Microenvironment
Glioma
Immunotherapy
Immunity
Neoplasms
Monoclonal Antibodies
Cytokines
Therapeutics

Keywords

  • CTLA-4
  • Glioblastoma multiforme
  • Immune checkpoint
  • PD-1

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

The role of checkpoints in the treatment of GBM. / Kim, Jennifer E.; Lim, Michael.

In: Journal of Neuro-Oncology, Vol. 123, No. 3, 23.07.2015, p. 413-423.

Research output: Contribution to journalArticle

Kim, Jennifer E. ; Lim, Michael. / The role of checkpoints in the treatment of GBM. In: Journal of Neuro-Oncology. 2015 ; Vol. 123, No. 3. pp. 413-423.
@article{26fcd07bcee44189b9b55922d55e961f,
title = "The role of checkpoints in the treatment of GBM",
abstract = "Targeted immunotherapy is founded on the principle that augmentation of effector T cell activity in the tumor microenvironment can translate to tumor regression. Targeted checkpoint inhibitors in the form of agonist or antagonist monoclonal antibodies have come to the fore as a promising strategy to activate systemic immunity and enhance T cell activity by blocking negative signals, enhancing positive signals, or altering the cytokine milieu. This review will examine several immune checkpoints and checkpoint modulators that play a role in cancer pathogenesis, with an emphasis on malignant gliomas.",
keywords = "CTLA-4, Glioblastoma multiforme, Immune checkpoint, PD-1",
author = "Kim, {Jennifer E.} and Michael Lim",
year = "2015",
month = "7",
day = "23",
doi = "10.1007/s11060-015-1747-8",
language = "English (US)",
volume = "123",
pages = "413--423",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - The role of checkpoints in the treatment of GBM

AU - Kim, Jennifer E.

AU - Lim, Michael

PY - 2015/7/23

Y1 - 2015/7/23

N2 - Targeted immunotherapy is founded on the principle that augmentation of effector T cell activity in the tumor microenvironment can translate to tumor regression. Targeted checkpoint inhibitors in the form of agonist or antagonist monoclonal antibodies have come to the fore as a promising strategy to activate systemic immunity and enhance T cell activity by blocking negative signals, enhancing positive signals, or altering the cytokine milieu. This review will examine several immune checkpoints and checkpoint modulators that play a role in cancer pathogenesis, with an emphasis on malignant gliomas.

AB - Targeted immunotherapy is founded on the principle that augmentation of effector T cell activity in the tumor microenvironment can translate to tumor regression. Targeted checkpoint inhibitors in the form of agonist or antagonist monoclonal antibodies have come to the fore as a promising strategy to activate systemic immunity and enhance T cell activity by blocking negative signals, enhancing positive signals, or altering the cytokine milieu. This review will examine several immune checkpoints and checkpoint modulators that play a role in cancer pathogenesis, with an emphasis on malignant gliomas.

KW - CTLA-4

KW - Glioblastoma multiforme

KW - Immune checkpoint

KW - PD-1

UR - http://www.scopus.com/inward/record.url?scp=84937512984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937512984&partnerID=8YFLogxK

U2 - 10.1007/s11060-015-1747-8

DO - 10.1007/s11060-015-1747-8

M3 - Article

C2 - 25749875

AN - SCOPUS:84937512984

VL - 123

SP - 413

EP - 423

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -